welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy
study id #: NCT03039686
condition: Duchenne Muscular Dystrophy
status: active, not recruiting
purpose:This is a multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of two different weekly doses of RO7239361 in ambulatory boys with Duchenne Muscular Dystrophy (DMD).
intervention: RO7239361, Placebo for RO7239361
mechanism of action: Anti-myostatin adnectin to promote muscle growth
results: https://clinicaltrials.gov/ct2/show/results/NCT03039686
last updated: November 02, 2019
rareRelated
-
HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)Male subjects with cardiomyopathy second...
-
An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular DystrophyThis study is an open-label extension to...
-
A Study of Tadalafil for Duchenne Muscular DystrophyThe main purpose of this study is to det...
-
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-2)HOPE-2 is a double-blind clinical trial ...
-
Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy (PolarisDMD)The PolarisDMD study is a Phase 3, globa...
-
A 2-Part Study to Assess the Safety and Tolerability, pk, Effects on Histology and Some Clinical Parameters of Givin...This is a 2-part, phase 2 study to asses...
-
A phase 2 trial of the safety and pharmacokinetics of ataluren in patients aged 2 to 5 years with nonsense mutation ...Nonsense mutation Duchenne muscular dyst...
-
Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-infl...We report a first-in-patient study of va...
-
Solid Biosciences Reports Third Quarter 2018 Financial Results And Provides Business UpdateSolid Biosciences Inc. today reported fi...
-
Catabasis Quarterly: Updates on edasalonexent and clinical trialsWe are pleased to announce that we have ...
-
PhaseOut DMD: a Phase 2, proof of concept, clinical study of utrophin modulation with ezutromidThis study investigates the hypothesis t...